Minervini Trend Template (SEPA)
TRADE-OFFSuperperformance stocks are in confirmed stage-2 uptrends before their biggest gains; an eight-point template filters for them.
How this run differs from the source: The trend template only; SEPA's earnings and sales tests, the base, the pivot entry and the stop are left out.
| THE STRATEGY | $SPXTR BUY & HOLD | |
|---|---|---|
| CAGR | 13.2% | 9.3% |
| Sharpe ratio | 0.51 | 0.66 |
| Max drawdown | -69.4% | -50.9% |
// GROWTH OF $1, LOG SCALE
Out-of-sample (from the split): CAGR 11.5% against 14.0% for the benchmark; Sharpe 0.52 in-sample, 0.48 out-of-sample.
After 25 bps of trading costs: 9.1% a year. WITHIN RANDOM
// DECADE BY DECADE
| ERA | STRATEGY | BENCHMARK |
|---|---|---|
| 1990s | 146.3% | 20.9% |
| 2000s | -3.0% | -0.8% |
| 2010s | 11.6% | 14.0% |
| 2020s | 15.3% | 15.2% |
// YEAR BY YEAR, LOSING YEARS IN RED
Losing years: 2000 (-36.5%), 2001 (-3.6%), 2002 (-17.1%), 2006 (-3.5%), 2008 (-32.5%), 2009 (-7.6%), 2011 (-18.6%), 2014 (-22.1%), 2015 (-8.6%), 2017 (-2.1%), 2018 (-9.6%), 2022 (-9.2%), 2023 (-1.2%), 2026 (-4.8%). Each cell: the strategy, then the benchmark below it. * a part year.
// THE IDEA, AS PUBLISHED
Mark Minervini, 'Trade Like a Stock Market Wizard' (2013) · 2013
- Price above the 150d and 200d MA; 150d above 200d
- 200d MA rising for at least 1 month (preferably 4-5)
- 50d above 150d and 200d; price above 50d
- Price 30%+ above 52-week low and within 25% of 52-week high
- RS ranking 70+ (prefer 80-90+)
A real computation on the QuantGPT warehouse, walk-forward. A study across the whole market includes only part of the companies that later delisted from 1998 (survivors only before); a study on your own list of tickers is not affected. Gross returns, no costs except where stated. Past performance is not a promise. Findings, not advice. COMPUTED 2026-11-07 04:46 ON THE QUANTGPT WAREHOUSE. COMPANIES THAT LATER DELISTED ARE ONLY PARTLY IN THIS UNIVERSE (A FIX IS IN PROGRESS), SO THE RESULT LEANS TOWARD SURVIVORS. FUNDAMENTALS BY FILING DATE. NOT INVESTMENT ADVICE. PRIVACY